Intrathecal baclofen withdrawal syndrome caused by low residual volume in the pump reservoir: A report of 2 cases

2004 ◽  
Vol 85 (12) ◽  
pp. 2064-2066 ◽  
Author(s):  
Gianfranco Rigoli ◽  
Giovanni Terrini ◽  
Zeno Cordioli
2010 ◽  
Vol 8 (7) ◽  
pp. 537
Author(s):  
W.R. Muirhead ◽  
N. Baylem ◽  
I. Jalloh ◽  
M. Vloeberghs

2009 ◽  
Vol 34 (6) ◽  
pp. 600-602 ◽  
Author(s):  
Anke Bellinger ◽  
Rapipen Siriwetchadarak ◽  
Richard Rosenquist ◽  
Jeremy D.W. Greenlee

2005 ◽  
Vol 102 (6) ◽  
pp. 1133-1136 ◽  
Author(s):  
Andrea F. Douglas ◽  
Howard L. Weiner ◽  
David R. Schwartz

✓ The authors describe a patient who experienced a prolonged course of intrathecal baclofen withdrawal syndrome after removal of an implantable baclofen pump for treatment of pump infection and meningitis. The current literature outlines management options for the acute management of this syndrome. In this report the authors discuss the long-term presentation of this syndrome and suggest a treatment strategy for management of the syndrome. A 37-year-old man who presented with a baclofen pump infection and meningitis experienced acute onset of intrathecal baclofen withdrawal syndrome 12 hours after the pump had been surgically removed. The patient's symptoms evolved into a severe, treatment-refractory withdrawal syndrome lasting longer than 1 month. Oral baclofen replacement with adjunctive administration of parenteral γ-aminobutyric acid agonists only served to stabilize the patient's critical condition throughout his hospital course. Replacement of the baclofen pump and restoration of intrathecal delivery of the medication was necessary to trigger the patient's dramatic recovery and complete reversal of the withdrawal syndrome within approximately 48 hours. These findings indicate that a more direct method of treating infected baclofen pumps than immediate surgical removal is necessary to prevent the onset of intrathecal baclofen withdrawal syndrome. Various options for preventing the onset of the syndrome while simultaneously treating the infection are discussed.


2007 ◽  
Vol 88 (11) ◽  
pp. 1468-1471 ◽  
Author(s):  
Colby R. Hansen ◽  
Judith L. Gooch ◽  
Teresa Such-Neibar

2021 ◽  
Vol 9 ◽  
pp. 205031212110221
Author(s):  
Jia W Romito ◽  
Emily R Turner ◽  
John A Rosener ◽  
Landon Coldiron ◽  
Ashutosh Udipi ◽  
...  

Baclofen is an effective therapeutic for the treatment of spasticity related to multiple sclerosis, spinal cord injuries, and other spinal cord pathologies. It has been increasingly used off-label for the management of several disorders, including musculoskeletal pain, gastroesophageal reflux disease, and alcohol use disorder. Baclofen therapy is associated with potential complications, including life-threatening toxicity and withdrawal syndrome. These disorders require prompt recognition and a high index of suspicion. While these complications can develop following administration of either oral or intrathecal baclofen, the risk is greater with the intrathecal route. The management of baclofen toxicity is largely supportive while baclofen withdrawal syndrome is most effectively treated with re-initiation or supplementation of baclofen dosing. Administration of other pharmacologic adjuncts may be required to effectively treat associated withdrawal symptoms. This narrative review provides an overview of the historical and emerging uses of baclofen, offers practical dosing recommendations for both oral and intrathecal routes of administration, and reviews the diagnosis and management of both baclofen toxicity and withdrawal.


Sign in / Sign up

Export Citation Format

Share Document